Valneva has announced positive outcomes from its Phase III trial of the single-shot IXCHIQ chikungunya virus vaccine in ...

Valneva SE VALN, a specialty vaccine company, recently reported positive Phase 3 - VLA1553-321 data in adolescents (12 to 17 ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ® ...

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus (CHIKV) vaccine in adolescents. The trial demonstrated a ‘sustained ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.

The FDA granted Priority Review to the BLA for CHIKV VLP, an adjuvanted virus-like particle (VLP)-based vaccine candidate for active immunization to prevent disease caused by chikungunya virus ...

Climate change could wreak havoc on Britain in coming decades, with rising food poisoning, allergies and the arrival of ...

We all know that a healthy, balanced diet dominated by unprocessed foods is a recipe for gut and overall health, but ...

Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Valneva in a research note ...

Future Virology. 2008;3(2):179-192. Although not listed as a hemorrhagic fever virus, illness caused by CHIKV can be confused with diseases such as dengue or yellow fever, based on the similarity ...